Safety and Toxicity
The CDRI (Central Drug Research
Institute) Lucknow, conducted the following studies in mice rats, rabbits, and
* acute toxicity
* subacute and chronic toxicity
* teratogenic and mutagenic
The results indicated that GugulipidÒ extract was safe for human consumption.
A four-week, phase 1 (safety on chronic administration)
study was conducted on 21 subjects with the following conditions.
* 9 patients with Hypertension
* 3 patients with IHD
* 2 patients with Diabetes Mellitus
* 3 patients with Diabetes Mellitus & Hypertension
* 3 patients with IHD & Hypertension
* 1 patient with Gout
All subjects received 400 mg of GugulipidÒ three times a day (equivalent to 25 mg of
guggulsterones). No adverse effects were reported for liver function, blood glucose, blood
urea levels, hematological parameters, or electrocardiogram results. Only one patient
complained of epigastric fullness three days after GugulipidÒadministration
that was controlled by antacids.
have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, cure, or prevent any disease"
Copyright © Sabinsa Corporation. All Rights Reserved